Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions.
about
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohortsA prospective study of height and body mass index in childhood, birth weight, and risk of adult glioma over 40 years of follow-upGenes that may modulate longevity in C. elegans in both dauer larvae and long-lived daf-2 adultsMagneto-optical relaxation measurements of functionalized nanoparticles as a novel biosensorIntracellular insulin-like growth factor-1 induces Bcl-2 expression in airway epithelial cellsType I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cellsInsulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2.Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.Cell and molecular mechanisms of insulin-induced angiogenesis.Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriersA nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosisEwing sarcoma: prognostic criteria, outcomes and future treatment.Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriersEvaluation of Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Expression Levels in Patients with Chronic Lymphocytic Leukemia.IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker.Insulin-like growth factor II in hepatocellular carcinoma.Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review.Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis.In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells.Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.
P2860
Q26752780-32272866-1B9B-4B5F-B68C-731B8CB14B1AQ26827810-4A1353B6-5FE4-41C8-B121-6D4908253F44Q28211600-2F0D1CDC-D6FD-45F8-A344-4A30C51799A0Q28395485-786179C8-A1A1-445F-B2C4-A2802CAF42B3Q33286458-C62CACD2-C79E-4EA3-9760-37491B04F238Q34191245-86827BD6-3AB7-48B2-AD6D-40C85F6F1F8FQ34213697-8AE4D8EA-C5C6-4467-BE75-B6B03D0187FDQ35012773-C96B4413-8DFD-41B6-832C-527822CF26F4Q35110943-36854515-22D1-4BD4-BB34-05B49DD2A592Q35524233-22AD1137-97BF-4D27-A962-EE79A7C206AAQ35889110-BED8328B-79C2-4A75-B7DC-E1E6344DB770Q35961713-FBC00805-FFAA-407B-9A36-D072E37727F9Q36152991-C1C87B0D-819F-4911-AB9A-58648C0AEBA9Q36190553-E0E72ED1-9DE9-493A-BDCA-ED2390C4964EQ37134450-818087CB-DFBD-49CF-A71A-655D8B6FEBCBQ37287506-914371EA-DA37-4DF7-AC9A-D0AFFCA233BCQ37349748-57F5CF52-0006-4B16-BAF6-C7E77AFD9825Q37467266-A9F5B02F-C086-4B42-9EFB-F4E0181D12AEQ37548270-83D936DB-A993-4877-9437-A125104464CFQ37708763-A0277A08-8F63-419B-9B27-AD5717CBF730Q37755101-79118978-0FAB-4CF9-BC6C-6A86197A44F2Q37890195-CD5568E0-C3C5-4A31-BF38-B947877250D2Q38069964-0646C625-27E4-479E-842E-4E729DF9AFA4Q38850952-431E89A1-7F6B-4D14-BE85-C192105B5DABQ39959245-5DEC2F1D-7E62-4173-9AB9-53D8FAC42360Q47435335-1A04F1F6-910B-4852-BC6D-92CF22896916Q51085085-F87F67F6-241A-4E7D-B5D6-2785740652BCQ55220517-08F8C1BD-BB83-4311-918D-7A0C06DC0775
P2860
Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Deregulation of the IGF axis i ...... ial therapeutic interventions.
@ast
Deregulation of the IGF axis i ...... ial therapeutic interventions.
@en
type
label
Deregulation of the IGF axis i ...... ial therapeutic interventions.
@ast
Deregulation of the IGF axis i ...... ial therapeutic interventions.
@en
prefLabel
Deregulation of the IGF axis i ...... ial therapeutic interventions.
@ast
Deregulation of the IGF axis i ...... ial therapeutic interventions.
@en
P2093
P356
P1476
Deregulation of the IGF axis i ...... ial therapeutic interventions.
@en
P2093
Leyland-Jones B
P304
P356
10.1677/ERC.0.0100561
P577
2003-12-01T00:00:00Z